New Strategies Enhance Care in mUC
OncLive,
— Although metastatic urothelial carcinoma remains generally incurable, management of bladder cancer has witnessed several…
Rucaparib for recurrent, locally advanced, or metastatic urothelial carcinoma (mUC): Results from ATLAS, a phase II open-label trial.
Overview of attention for article published in Journal of Clinical Oncology, February 2020
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
Good Attention Score compared to outputs of the same age (74th percentile)
-
Average Attention Score compared to outputs of the same age and source
Readers on
- mendeley
- 11 Mendeley